The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial pathology tissue resource

Claire S. Zhu, Wen Yi Huang, Paul F. Pinsky, Christine D. Berg, Mark E. Sherman, Kelly J. Yu, Danielle M. Carrick, Amanda Black, Robert Hoover, Petra Lenz, Craig Williams, Laura Hawkins, Matthew Chaloux, Susan Yurgalevitch, Sunitha Mathew, Amy Miller, Vanessa Olivo, Asia Khan, Shannon M. Pretzel, Deborah MultererPatricia Beckmann, Karen G. Broski, Neal D. Freedman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Pathology tissue specimens with associated epidemiologic and clinical data are valuable for cancer research. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial undertook a large-scale effort to create a public resource of pathology tissues from PLCO participants who developed a cancer during the trial. Methods: Formalin-fixed paraffin-embedded tissue blocks were obtained from pathology laboratories on a loan basis for central processing of tissue microarrays, with additional free-standing tissue cores collected for nucleic acid extraction. Results: Pathology tissue specimens were obtained for prostate cancer (n = 1,052), lung cancer (n = 434), colorectal cancer (n=675) and adenoma (n=658), ovarian cancer and borderline tumors (n = 212), breast cancer (n = 870), and bladder cancer (n = 204). The process of creating this resource was complex, involving multidisciplinary teams with expertise in pathology, epidemiology, information technology, project management, and specialized laboratories. Conclusions: Creating the PLCO tissue resource required a multistep process, including obtaining medical records and contacting pathology departments where pathology materials were stored after obtaining necessary patient consent and authorization. The potential to link tissue biomarkers to prospectively collected epidemiologic information, screening and clinical data, and matched blood or buccal samples offers valuable opportunities to study etiologic heterogeneity, mechanisms of carcinogenesis, and biomarkers for early detection and prognosis. Impact: The methods and protocols developed for this effort, and the detailed description of this resource provided here, will be useful for those seeking to use PLCO pathology tissue specimens for their research and may also inform future tissue collection efforts in other settings.

Original languageEnglish (US)
Pages (from-to)1635-1642
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume25
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Early Detection of Cancer
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Pathology
Biomarkers
Neoplasms
Cheek
Research
Urinary Bladder Neoplasms
Adenoma
Paraffin
Nucleic Acids
Formaldehyde
Medical Records
Carcinogenesis
Epidemiology
Breast Neoplasms
Technology

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial pathology tissue resource. / Zhu, Claire S.; Huang, Wen Yi; Pinsky, Paul F.; Berg, Christine D.; Sherman, Mark E.; Yu, Kelly J.; Carrick, Danielle M.; Black, Amanda; Hoover, Robert; Lenz, Petra; Williams, Craig; Hawkins, Laura; Chaloux, Matthew; Yurgalevitch, Susan; Mathew, Sunitha; Miller, Amy; Olivo, Vanessa; Khan, Asia; Pretzel, Shannon M.; Multerer, Deborah; Beckmann, Patricia; Broski, Karen G.; Freedman, Neal D.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 25, No. 12, 01.12.2016, p. 1635-1642.

Research output: Contribution to journalArticle

Zhu, CS, Huang, WY, Pinsky, PF, Berg, CD, Sherman, ME, Yu, KJ, Carrick, DM, Black, A, Hoover, R, Lenz, P, Williams, C, Hawkins, L, Chaloux, M, Yurgalevitch, S, Mathew, S, Miller, A, Olivo, V, Khan, A, Pretzel, SM, Multerer, D, Beckmann, P, Broski, KG & Freedman, ND 2016, 'The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial pathology tissue resource', Cancer Epidemiology Biomarkers and Prevention, vol. 25, no. 12, pp. 1635-1642. https://doi.org/10.1158/1055-9965.EPI-16-0506
Zhu, Claire S. ; Huang, Wen Yi ; Pinsky, Paul F. ; Berg, Christine D. ; Sherman, Mark E. ; Yu, Kelly J. ; Carrick, Danielle M. ; Black, Amanda ; Hoover, Robert ; Lenz, Petra ; Williams, Craig ; Hawkins, Laura ; Chaloux, Matthew ; Yurgalevitch, Susan ; Mathew, Sunitha ; Miller, Amy ; Olivo, Vanessa ; Khan, Asia ; Pretzel, Shannon M. ; Multerer, Deborah ; Beckmann, Patricia ; Broski, Karen G. ; Freedman, Neal D. / The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial pathology tissue resource. In: Cancer Epidemiology Biomarkers and Prevention. 2016 ; Vol. 25, No. 12. pp. 1635-1642.
@article{a15848ef37254272b1340375e79688c4,
title = "The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial pathology tissue resource",
abstract = "Background: Pathology tissue specimens with associated epidemiologic and clinical data are valuable for cancer research. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial undertook a large-scale effort to create a public resource of pathology tissues from PLCO participants who developed a cancer during the trial. Methods: Formalin-fixed paraffin-embedded tissue blocks were obtained from pathology laboratories on a loan basis for central processing of tissue microarrays, with additional free-standing tissue cores collected for nucleic acid extraction. Results: Pathology tissue specimens were obtained for prostate cancer (n = 1,052), lung cancer (n = 434), colorectal cancer (n=675) and adenoma (n=658), ovarian cancer and borderline tumors (n = 212), breast cancer (n = 870), and bladder cancer (n = 204). The process of creating this resource was complex, involving multidisciplinary teams with expertise in pathology, epidemiology, information technology, project management, and specialized laboratories. Conclusions: Creating the PLCO tissue resource required a multistep process, including obtaining medical records and contacting pathology departments where pathology materials were stored after obtaining necessary patient consent and authorization. The potential to link tissue biomarkers to prospectively collected epidemiologic information, screening and clinical data, and matched blood or buccal samples offers valuable opportunities to study etiologic heterogeneity, mechanisms of carcinogenesis, and biomarkers for early detection and prognosis. Impact: The methods and protocols developed for this effort, and the detailed description of this resource provided here, will be useful for those seeking to use PLCO pathology tissue specimens for their research and may also inform future tissue collection efforts in other settings.",
author = "Zhu, {Claire S.} and Huang, {Wen Yi} and Pinsky, {Paul F.} and Berg, {Christine D.} and Sherman, {Mark E.} and Yu, {Kelly J.} and Carrick, {Danielle M.} and Amanda Black and Robert Hoover and Petra Lenz and Craig Williams and Laura Hawkins and Matthew Chaloux and Susan Yurgalevitch and Sunitha Mathew and Amy Miller and Vanessa Olivo and Asia Khan and Pretzel, {Shannon M.} and Deborah Multerer and Patricia Beckmann and Broski, {Karen G.} and Freedman, {Neal D.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1158/1055-9965.EPI-16-0506",
language = "English (US)",
volume = "25",
pages = "1635--1642",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - The prostate, lung, colorectal and ovarian cancer (PLCO) screening trial pathology tissue resource

AU - Zhu, Claire S.

AU - Huang, Wen Yi

AU - Pinsky, Paul F.

AU - Berg, Christine D.

AU - Sherman, Mark E.

AU - Yu, Kelly J.

AU - Carrick, Danielle M.

AU - Black, Amanda

AU - Hoover, Robert

AU - Lenz, Petra

AU - Williams, Craig

AU - Hawkins, Laura

AU - Chaloux, Matthew

AU - Yurgalevitch, Susan

AU - Mathew, Sunitha

AU - Miller, Amy

AU - Olivo, Vanessa

AU - Khan, Asia

AU - Pretzel, Shannon M.

AU - Multerer, Deborah

AU - Beckmann, Patricia

AU - Broski, Karen G.

AU - Freedman, Neal D.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Pathology tissue specimens with associated epidemiologic and clinical data are valuable for cancer research. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial undertook a large-scale effort to create a public resource of pathology tissues from PLCO participants who developed a cancer during the trial. Methods: Formalin-fixed paraffin-embedded tissue blocks were obtained from pathology laboratories on a loan basis for central processing of tissue microarrays, with additional free-standing tissue cores collected for nucleic acid extraction. Results: Pathology tissue specimens were obtained for prostate cancer (n = 1,052), lung cancer (n = 434), colorectal cancer (n=675) and adenoma (n=658), ovarian cancer and borderline tumors (n = 212), breast cancer (n = 870), and bladder cancer (n = 204). The process of creating this resource was complex, involving multidisciplinary teams with expertise in pathology, epidemiology, information technology, project management, and specialized laboratories. Conclusions: Creating the PLCO tissue resource required a multistep process, including obtaining medical records and contacting pathology departments where pathology materials were stored after obtaining necessary patient consent and authorization. The potential to link tissue biomarkers to prospectively collected epidemiologic information, screening and clinical data, and matched blood or buccal samples offers valuable opportunities to study etiologic heterogeneity, mechanisms of carcinogenesis, and biomarkers for early detection and prognosis. Impact: The methods and protocols developed for this effort, and the detailed description of this resource provided here, will be useful for those seeking to use PLCO pathology tissue specimens for their research and may also inform future tissue collection efforts in other settings.

AB - Background: Pathology tissue specimens with associated epidemiologic and clinical data are valuable for cancer research. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial undertook a large-scale effort to create a public resource of pathology tissues from PLCO participants who developed a cancer during the trial. Methods: Formalin-fixed paraffin-embedded tissue blocks were obtained from pathology laboratories on a loan basis for central processing of tissue microarrays, with additional free-standing tissue cores collected for nucleic acid extraction. Results: Pathology tissue specimens were obtained for prostate cancer (n = 1,052), lung cancer (n = 434), colorectal cancer (n=675) and adenoma (n=658), ovarian cancer and borderline tumors (n = 212), breast cancer (n = 870), and bladder cancer (n = 204). The process of creating this resource was complex, involving multidisciplinary teams with expertise in pathology, epidemiology, information technology, project management, and specialized laboratories. Conclusions: Creating the PLCO tissue resource required a multistep process, including obtaining medical records and contacting pathology departments where pathology materials were stored after obtaining necessary patient consent and authorization. The potential to link tissue biomarkers to prospectively collected epidemiologic information, screening and clinical data, and matched blood or buccal samples offers valuable opportunities to study etiologic heterogeneity, mechanisms of carcinogenesis, and biomarkers for early detection and prognosis. Impact: The methods and protocols developed for this effort, and the detailed description of this resource provided here, will be useful for those seeking to use PLCO pathology tissue specimens for their research and may also inform future tissue collection efforts in other settings.

UR - http://www.scopus.com/inward/record.url?scp=85006287974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006287974&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-16-0506

DO - 10.1158/1055-9965.EPI-16-0506

M3 - Article

C2 - 27635065

AN - SCOPUS:85006287974

VL - 25

SP - 1635

EP - 1642

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -